PAIA
BIIB icon

Park Avenue Institutional Advisers’s Biogen BIIB Stock Holding History

Park Avenue Institutional Advisers’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,382
Closed -$334K – 61
2016
Q2 		$334K Sell
1,382
-23
-2% -$6.06K 0.29% 84
2016
Q1 		$366K Sell
1,405
-39
-3% -$10.3K 0.32% 75
2015
Q4 		$442K Sell
1,444
-121
-8% -$34.8K 0.38% 61
2015
Q3 		$457K Sell
1,565
-18
-1% -$5.94K 0.4% 59
2015
Q2 		$639K Buy
+1,583
New +$635K 0.51% 45

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Park Avenue Institutional Advisers's BIIB Position: Q3 2016 in Review

Park Avenue Institutional Advisers sold out of Biogen (BIIB) in Q3 2016, closing a stake of 1,382 shares — an estimated $334K sold.

Park Avenue Institutional Advisers first reported a position in BIIB in Q2 2015 and held it in 5 quarters. The position peaked at $639K in Q2 2015. 1,014 funds tracked by Wall St. Rank hold BIIB as of Q3 2016.

  • Park Avenue Institutional Advisers reported no remaining Biogen position as of Q3 2016 after selling out during the quarter.
  • Park Avenue Institutional Advisers sold 1,382 Biogen shares in Q3 2016, an estimated $334K.
  • Park Avenue Institutional Advisers first reported a position in Biogen in Q2 2015 and held it in 5 quarters.
  • Park Avenue Institutional Advisers's Biogen position peaked at $639K in Q2 2015.
  • 1,014 funds tracked by Wall St. Rank held Biogen as of Q3 2016.

Based on Park Avenue Institutional Advisers's 13F filing for Q3 2016, filed 15 Feb 2017.